Healthcare of Ontario Pension Plan Trust Fund Invests $8.19 Million in Jazz Pharmaceuticals PLC $JAZZ

Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) in the 1st quarter, Holdings Channel reports. The firm acquired 43,300 shares of the specialty pharmaceutical company’s stock, valued at approximately $8,186,000.

Other institutional investors also recently modified their holdings of the company. LRI Investments LLC bought a new position in Jazz Pharmaceuticals during the fourth quarter worth $38,000. Westpac Banking Corp bought a new stake in Jazz Pharmaceuticals in the first quarter valued at $51,000. Leonteq Securities AG bought a new stake in Jazz Pharmaceuticals in the fourth quarter valued at $50,000. Root Financial Partners LLC raised its holdings in shares of Jazz Pharmaceuticals by 42.8% during the first quarter. Root Financial Partners LLC now owns 297 shares of the specialty pharmaceutical company’s stock valued at $56,000 after purchasing an additional 89 shares during the period. Finally, Danske Bank A S acquired a new position in shares of Jazz Pharmaceuticals during the third quarter valued at about $40,000. Institutional investors and hedge funds own 89.14% of the company’s stock.

Insider Buying and Selling at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, Director Mark Douglas Smith sold 1,157 shares of Jazz Pharmaceuticals stock in a transaction on Monday, June 15th. The shares were sold at an average price of $230.55, for a total transaction of $266,746.35. Following the transaction, the director directly owned 9,680 shares of the company’s stock, valued at $2,231,724. The trade was a 10.68% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Rick E. Winningham sold 2,741 shares of the company’s stock in a transaction on Friday, May 22nd. The stock was sold at an average price of $241.57, for a total transaction of $662,143.37. Following the completion of the sale, the director owned 9,567 shares of the company’s stock, valued at approximately $2,311,100.19. The trade was a 22.27% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 13,098 shares of company stock worth $3,131,906. 4.10% of the stock is currently owned by insiders.

Jazz Pharmaceuticals Trading Up 0.6%

NASDAQ:JAZZ opened at $256.92 on Wednesday. The company has a debt-to-equity ratio of 0.95, a current ratio of 2.04 and a quick ratio of 1.85. The firm has a 50-day moving average of $238.28 and a 200-day moving average of $204.68. The company has a market cap of $16.14 billion, a PE ratio of -12,839.58, a PEG ratio of 0.23 and a beta of 0.32. Jazz Pharmaceuticals PLC has a one year low of $105.00 and a one year high of $261.30.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share for the quarter. The business had revenue of $1.07 billion for the quarter. Jazz Pharmaceuticals had a net margin of 0.66% and a return on equity of 14.56%. As a group, equities research analysts expect that Jazz Pharmaceuticals PLC will post 21.9 EPS for the current fiscal year.

Analysts Set New Price Targets

JAZZ has been the subject of several research reports. Robert W. Baird set a $252.00 target price on Jazz Pharmaceuticals in a research note on Wednesday, May 6th. Raymond James Financial reaffirmed an “outperform” rating and set a $239.00 price target on shares of Jazz Pharmaceuticals in a research note on Wednesday, May 6th. Leerink Partners increased their price target on Jazz Pharmaceuticals from $215.00 to $225.00 and gave the stock an “outperform” rating in a report on Wednesday, April 22nd. Wells Fargo & Company raised their price objective on Jazz Pharmaceuticals from $265.00 to $285.00 and gave the company an “overweight” rating in a research note on Tuesday, July 14th. Finally, Needham & Company LLC boosted their price objective on Jazz Pharmaceuticals from $255.00 to $282.00 and gave the company a “buy” rating in a report on Monday, July 20th. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, Jazz Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $259.06.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.